161 related articles for article (PubMed ID: 12848769)
1. Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology.
Belz GG
Br J Clin Pharmacol; 2003 Jul; 56(1):3-10. PubMed ID: 12848769
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.
Breithaupt-Grögler K; Malerczyk C; Belz GG; Butzer R; Herrmann V; Stass H; Wensing G
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):434-41. PubMed ID: 9352392
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
Belz GG; Butzer R; Kober S; Mutschler E
J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens; 2001 Dec; 19(12):2241-50. PubMed ID: 11725169
[TBL] [Abstract][Full Text] [Related]
5. The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man.
Belz GG; Breithaupt-Grögler K; Butzer R; Fuchs W; Hausdorf C; Mang C
J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):336-41. PubMed ID: 11967820
[TBL] [Abstract][Full Text] [Related]
6. Sympatho-inhibitory properties of various AT1 receptor antagonists.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.
Malerczyk C; Fuchs B; Belz GG; Roll S; Butzer R; Breithaupt-Grögler K; Herrmann V; Magin SG; Högemann A; Voith B; Mutschler E
Br J Clin Pharmacol; 1998 Jun; 45(6):567-73. PubMed ID: 9663812
[TBL] [Abstract][Full Text] [Related]
8. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
Vanderheyden PM; Fierens FL; De Backer JP; Fraeyman N; Vauquelin G
Br J Pharmacol; 1999 Feb; 126(4):1057-65. PubMed ID: 10193788
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.
Wienen W; Hauel N; Van Meel JC; Narr B; Ries U; Entzeroth M
Br J Pharmacol; 1993 Sep; 110(1):245-52. PubMed ID: 8220885
[TBL] [Abstract][Full Text] [Related]
10. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
[TBL] [Abstract][Full Text] [Related]
11. Role of angiotensin AT1 and AT2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog.
Clark KL; Robertson MJ; Drew GM
Br J Pharmacol; 1993 May; 109(1):148-56. PubMed ID: 8495237
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the vascular and antiadrenergic activities of four angiotensin II type 1 antagonists in the pithed rat.
Dendorfer A; Raasch W; Tempel K; Dominiak P
J Hypertens; 2002 Jun; 20(6):1151-6. PubMed ID: 12023685
[TBL] [Abstract][Full Text] [Related]
13. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism.
Brilla CG; Scheer C; Rupp H
J Hypertens Suppl; 1997 Dec; 15(6):S13-9. PubMed ID: 9493122
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin(1-7) is an antagonist at the type 1 angiotensin II receptor.
Mahon JM; Carr RD; Nicol AK; Henderson IW
J Hypertens; 1994 Dec; 12(12):1377-81. PubMed ID: 7706697
[TBL] [Abstract][Full Text] [Related]
15. Regulation of angiotensin II receptor AT1 subtypes in renal afferent arterioles during chronic changes in sodium diet.
Ruan X; Wagner C; Chatziantoniou C; Kurtz A; Arendshorst WJ
J Clin Invest; 1997 Mar; 99(5):1072-81. PubMed ID: 9062366
[TBL] [Abstract][Full Text] [Related]
16. Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism.
Panek RL; Lu GH; Overhiser RW; Major TC; Hodges JC; Taylor DG
J Pharmacol Exp Ther; 1995 May; 273(2):753-61. PubMed ID: 7752078
[TBL] [Abstract][Full Text] [Related]
17. Differential development of umbilical and systemic arteries. I. ANG II receptor subtype expression.
Kaiser JR; Cox BE; Roy TA; Rosenfeld CR
Am J Physiol; 1998 Mar; 274(3):R797-807. PubMed ID: 9530248
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological differences among angiotensin II receptor antagonists.
Belz GG
Blood Press Suppl; 2001; 2():13-8. PubMed ID: 11465912
[TBL] [Abstract][Full Text] [Related]
19. Counteraction between angiotensin II and angiotensin-(1-7) via activating angiotensin type I and Mas receptor on rat renal mesangial cells.
Xue H; Zhou L; Yuan P; Wang Z; Ni J; Yao T; Wang J; Huang Y; Yu C; Lu L
Regul Pept; 2012 Aug; 177(1-3):12-20. PubMed ID: 22561449
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man.
Fuchs B; Breithaupt-Grögler K; Belz GG; Roll S; Malerczyk C; Herrmann V; Spahn-Langguth H; Mutschler E
J Pharm Pharmacol; 2000 Sep; 52(9):1075-83. PubMed ID: 11045887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
